| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell and Tumor Biology |
1 Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, Korea and 2 Cancer Research Institute and Cancer Research Center, Seoul National University, Seoul, Korea
Requests for reprints: Jae-Gahb Park, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi 411-764, Korea. Phone: 822-760-3380; Fax: 822-742-4727. E-mail: jgpark{at}plaza.snu.ac.kr.
Abstract
5-Fluorouracil (5-FU) is widely used for treatment of advanced colorectal cancer. However, it is common for such patients to develop resistance to 5-FU, and this drug resistance becomes a critical problem for chemotherapy. The mechanisms underlying this resistance are largely unknown. To screen for proteins possibly responsible for 5-FU resistance, cells resistant to 5-FU were derived from human colon cancer cell lines and two-dimensional gel electrophoresisbased comparative proteomics was done. Two-dimensional gel electrophoresis data showed there was lower expression of the
subunit of mitochondrial F1F0-ATP synthase (ATP synthase) in 5-FUresistant cells compared with parent cells. Western blotting showed that expression of other ATP synthase complex subunits was also lower in 5-FUresistant cell lines and that these resistant cells also showed decreased ATP synthase activity and reduced intracellular ATP content. The ATP synthase inhibitor, oligomycin A, strongly antagonized 5-FUinduced suppression of cell proliferation. When 5-FU sensitivity was compared with ATP synthase activity in six different human colon cancer cell lines, a positive correlation has been found. Furthermore, suppressed ATP synthase d-subunit expression by siRNA transfection increased cell viability in the presence of 5-FU. Bioenergetic dysfunction of mitochondria has been reported as a hallmark of many types of cancers (i.e., down-regulation of ATP synthase ß-subunit expression in liver, kidney, colon, squamous oesophageal, and lung carcinomas, as well as in breast and gastric adenocarcinomas). Our findings show that ATP synthase down-regulation may not only be a bioenergetic signature of colorectal carcinomas but may also lead to cellular events responsible for 5-FU resistance.
This article has been cited by other articles:
![]() |
R Seth, J Keeley, G Abu-Ali, S Crook, D Jackson, and M Ilyas The putative tumour modifier gene ATP5A1 is not mutated in human colorectal cancer cell lines but expression levels correlate with TP53 mutations and chromosomal instability J. Clin. Pathol., July 1, 2009; 62(7): 598 - 603. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Ortega, S. Sala, E. Espinosa, M. Gonzalez-Baron, and J. M. Cuezva HuR and the bioenergetic signature of breast cancer: a low tumor expression of the RNA-binding protein predicts a higher risk of disease recurrence Carcinogenesis, November 1, 2008; 29(11): 2053 - 2061. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Lopez-Rios, M. Sanchez-Arago, E. Garcia-Garcia, A. D. Ortega, J. R. Berrendero, F. Pozo-Rodriguez, A. Lopez-Encuentra, C. Ballestin, and J. M. Cuezva Loss of the Mitochondrial Bioenergetic Capacity Underlies the Glucose Avidity of Carcinomas Cancer Res., October 1, 2007; 67(19): 9013 - 9017. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Chi, M. L. Wahl, Y. M. Mowery, S. Shan, S. Mukhopadhyay, S. C. Hilderbrand, D. J. Kenan, B. D. Lipes, C. E. Johnson, M. F. Marusich, et al. Angiostatin-Like Activity of a Monoclonal Antibody to the Catalytic Subunit of F1F0 ATP Synthase Cancer Res., May 15, 2007; 67(10): 4716 - 4724. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Baran, K. A. Silverman, J. Zeskand, R. Koratkar, A. Palmer, K. McCullen, W. J. Curran Jr, T. B. Edmonston, L. D. Siracusa, and A. M. Buchberg The modifier of Min 2 (Mom2) locus: Embryonic lethality of a mutation in the Atp5a1 gene suggests a novel mechanism of polyp suppression Genome Res., May 1, 2007; 17(5): 566 - 576. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Santamaria, M. Martinez-Diez, I. Fabregat, and J. M. Cuezva Efficient execution of cell death in non-glycolytic cells requires the generation of ROS controlled by the activity of mitochondrial H+-ATP synthase Carcinogenesis, May 1, 2006; 27(5): 925 - 935. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |